Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest update is out from Pelthos Therapeutics ( (PTHS) ).
On December 17, 2025, Pelthos Therapeutics Inc. conducted its 2025 Annual Meeting of Stockholders where three key proposals were addressed. The election of seven directors to the board was approved, ensuring leadership continuity until the 2026 Annual Meeting. Additionally, stockholders approved a proposal to waive share issuance limits tied to senior secured convertible notes and ratified the appointment of CBIZ CPAs P.C. as the company’s independent auditor for the fiscal year ending December 31, 2025. These decisions reflect robust stakeholder participation and support for the company’s strategic and operational positioning.
The most recent analyst rating on (PTHS) stock is a Buy with a $75.00 price target. To see the full list of analyst forecasts on Pelthos Therapeutics stock, see the PTHS Stock Forecast page.
More about Pelthos Therapeutics
Pelthos Therapeutics Inc. operates in the biopharmaceutical industry, focusing on developing and delivering therapeutic solutions for treating medical conditions. The company emphasizes advancing healthcare through innovative pharmaceutical products and services.
Average Trading Volume: 22,176
Technical Sentiment Signal: Buy
Current Market Cap: $67.38M
For a thorough assessment of PTHS stock, go to TipRanks’ Stock Analysis page.